SAB Biotherapeutics Past Earnings Performance
Past criteria checks 0/6
SAB Biotherapeutics's earnings have been declining at an average annual rate of -58.4%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 92.6% per year.
Key information
-58.4%
Earnings growth rate
-50.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -92.6% |
| Return on equity | -87.4% |
| Net Margin | -1,450.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
Sep 22
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified
Apr 17Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week
Jan 20Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues
Nov 19Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 18SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial
Sep 28What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates
Aug 12SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03
Aug 10Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term
Apr 06SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies
Dec 02Revenue & Expenses Breakdown
How SAB Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -40 | 25 | 0 |
| 31 Mar 24 | 3 | -40 | 25 | 0 |
| 31 Dec 23 | 2 | -42 | 24 | 0 |
| 30 Sep 23 | 4 | -27 | 12 | 0 |
| 30 Jun 23 | 6 | -29 | 13 | 0 |
| 31 Mar 23 | 13 | -27 | 15 | 0 |
| 31 Dec 22 | 24 | -19 | 16 | 0 |
| 30 Sep 22 | 33 | -22 | 21 | 0 |
| 30 Jun 22 | 44 | -19 | 21 | 0 |
| 31 Mar 22 | 56 | -18 | 19 | 0 |
| 31 Dec 21 | 61 | -17 | 17 | 0 |
| 30 Sep 21 | 76 | 7 | 10 | -11 |
| 30 Jun 21 | 78 | 17 | 10 | 0 |
| 31 Mar 21 | 66 | 21 | 9 | 0 |
| 31 Dec 20 | 55 | 20 | 7 | 0 |
| 31 Dec 19 | 3 | -9 | 4 | 0 |
Quality Earnings: SABS is currently unprofitable.
Growing Profit Margin: SABS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SABS is unprofitable, and losses have increased over the past 5 years at a rate of 58.4% per year.
Accelerating Growth: Unable to compare SABS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SABS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: SABS has a negative Return on Equity (-87.43%), as it is currently unprofitable.